Aummune is a clinical-stage company developing a novel, individualized immunotherapy for solid tumors. Their proprietary platform utilizes an efficacy-driven selection process to create patient-specific tri-functional oligonucleotide drugs that induce cancer cell death and activate immune responses. This approach aims to provide a new class of therapy for a broad spectrum of cancer indications.